Rebuilder Medical Technologies is in concluding stages of finalizing a national contract to provide billing services for all physicians

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it is in the final stages of negotiating a national contract to provide all physicians with billing services for Medicare claims for the ReBuilder.

Physicians all over the U.S. are now using the ReBuilder as their first choice for the treatment of leg pain. Many of them are not registered with Medicare so that they can provide the ReBuilder to their patients with little or no out of pocket cost to the patient.

"When we finish the final touches to this agreement," said David Phillips, Ph.D. CEO., "we will have national coverage for billing Medicare via a third party DME (durable medical equipment provider).

Additionally, Dr. Phillips reports: "With this in place, any physician can prescribe the ReBuilder for their patients in pain and a third party will handle all the claims processing and deliver and train the patient in the ReBuilder's proper use."

Finally, Dr. Phillips told reporters today: "We have waited a long time to get into this exciting phase of our business. This organization has already proven that they can efficiently manage the claims for over 30 patients. We expect to be able to send them at least 30 new cases per day."

http://www.rebuildermedical.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vial size could save Medicare millions on Alzheimer's drug